User:Mr. Ibrahem/Inclisiran

Inclisiran, sold under the brand name Leqvio, is a medication used to treat reduce cholesterol in the blood. It is used in primary hypercholesterolaemia or mixed dyslipidaemia together with a low fat diet, when a statin is not sufficient. This includes in heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD). It is given by injection under the skin.

Common side effects include injection site reaction, joint pain, urinary tract infection, diarrhea, bronchitis, pain in extremity, and shortness of breath. It is believed that use in pregnancy may harm the baby. Use appears relatively safe in those with kidney or liver problems. It is a small interfering RNA (siRNA) that inhibits the production of the protein PCSK9.

Inclisiran was approved for medical use in Europe in 2020 and the United States in 2021. In the United States it is available from specialty pharmacies. The cost to the NHS in the United Kingdom is undisclosed as of 2022; however, was about £2,000 per 284 mg syringe as of 2021. This amount in the United States is about 3,400 USD.